

14th International Congress on Cardiovascular Pharmacotherapy



November 29th - December 2nd, 2007
Sungate Port Royal Resort
Antalya / TURKEY



EUROPEAN
ATHEROSCLEROSIS
SOCIETY

SECOND ANNOUNCEMENT

www.iscp2007.org

Dear Colleagues,

It is a great pleasure for me to invite you to the 14th Congress of the International Society of Cardiovascular Pharmacotherapy (ISCP) which will be held in one of the pearls of the Mediterranean, Antalya, Turkey.

Over the last two decades the Congresses of the ISCP have always been major scientific events in the field of the medical therapy of the cardiovascular diseases and created a world forum for knowledge sharing and exchanging ideas. Clinical trials as the cornerstone of the evidence based cardiology and late breaking trials will be the new faces of the ISCP Congress in 2007 besides the continuation of the tradition.

Cardiovascular pharmacotherapy covers a wide spectrum of therapeutics and such a spectrum will be provided in the Congress from preventive drug therapy to gene based and cellular therapy.

The scientific platform, the collegial atmosphere and the historical and natural beauty of the venue show adequate evidence for choosing the 14th Congress of the ISCP to send your valuable works and to attend.

Looking forward to seeing you in Antalya,

A handwritten signature in black ink, appearing to read 'MAOT', with a horizontal line underneath the letters.

*Ali Oto, MD, FESC, FACC, FHRS
President of ISCP Congress 2007*

14th INTERNATIONAL CONGRESS ON CARDIOVASCULAR PHARMACOTHERAPY

ORGANIZING COMMITTEE

Ali Oto (Chairman)	Aytekin Oğuz
Ahmet Akıcı	Ahmet Oktay
İsmail Hakkı Ayhan	Şule Oktay
Kudret Aytemir	Hakan Orer
Aykan Canberk	Zeki Öngen
Oktay Ergene	Vedat Sansoy
Giray Kabakçı	Lale Tokgözoğlu
Ömer Kozan	Meral Tuncer
Haldun Müderrisoğlu	Yağız Üresin
Yılmaz Nişancı	

PROGRAM COMMITTEE

D. Atar (Denmark)	W. J. Louis (Australia)
A. Bayés de Luna (Spain)	J. Mc. Neil (Australia)
G. Breithardt (Germany)	A. Oto (Turkey)
A. J. Camm (UK)	P. A. Poole-Wilson (UK)
J. Cleland (UK)	K. Stoschitzky (Austria)
J. Cohn (USA)	L. Tokgözoğlu (Turkey)
H. Dayi (China)	W. H. van Gilst (The Netherlands)
S. Erdine (Turkey)	F. Verheugt (The Netherlands)


SCIENTIFIC ADVISORY BOARD

J. Abrams (USA)	H. Boudulas (Greece)	O. Ergene (Turkey)
C. Abreu-Lima (Portugal)	M. Böhm (Germany)	A. Erglis (Latvia)
E. Acartürk (Turkey)	A. Canberk (Turkey)	C. Ermiş (Turkey)
G. Adamyan (Armenia)	R. Capalleanu (Romania)	Ö. Ertürk (Turkey)
A. Akıcı (Turkey)	A. Capucci (Italy)	P. Esteves (Brazil)
M. Aksoy (Turkey)	V. Chumburidze (Georgia)	R. Ferrari (Italy)
A. Altun (Turkey)	A. Cieslinski (Poland)	F. Follath (Switzerland)
E. Ambrosioni (Italy)	A. Coelho (Brazil)	V. Fuster (USA)
G. Arnold (Germany)	D.V. Cokkinos (Greece)	R. Gao (China)
M. Aschermann (Czech Republic)	N. Çağlar (Turkey)	G. Ghanem (Lebanon)
N. Ata (Turkey)	N. Çam (Turkey)	C. Gillebert (Belgium)
İ.H. Ayhan (Turkey)	A. Damascano (Mozambique)	M. Glikson (Israel)
K. Aytemir (Turkey)	N. Danchin (France)	J.R. Gonzales-Juanatey (Spain)
S. Barold (USA)	M. Değertekin (Turkey)	N. Gotcheva (Bulgaria)
J. Bartolucci (Chile)	M. Demirtaş (Turkey)	C. Hamm (Germany)
I. Başar (Turkey)	R. Dietz (Germany)	H. Hansen (Denmark)
A. Battler (Israel)	E. Escobar (Chile)	H. Haouala (Tunisia)
H. Baumgartner (Austria)	M. Eldar (Israel)	J. Hartikainen (Finland)
J. Beissel (Luxembourg)	M. ElSahawy (USA)	F. Hidalgo (Equador)
C. Borghi (Italy)	N. El Sheriff (USA)	S. Higginson (Ireland)

SCIENTIFIC ADVISORY BOARD

- K. Hossack (Australia&New Zealand)
E. Işık (Turkey)
B. İlerigelen (Turkey)
E. İlkay (Turkey)
A. İyisoy (Turkey)
W. Jaarsma (The Netherlands)
I.M. Jashi (Georgia)
A. Jaussi (Switzerland)
C. Jazzra (Lebanon)
J. Jorgova (Bulgaria)
G. Kabakçı (Turkey)
S. Kabbani Syrian (Arab Republic)
A. Kamberi (Albania)
H. Karageuzian (USA)
J.C. Kaski (UK)
D.T. Kelly (Australia)
M. Kenda (Slovenia)
L. Koldaş (Turkey)
R. Kolk (Estonia)
B. Komsuoğlu (Turkey)
V. Kovalenko (Ukraine)
Ö. Kozan (Turkey)
S. Köse (Turkey)
H. Kurşaklıoğlu (Turkey)
H. Kültürsay (Turkey)
T. Kürüm (Turkey)
A. Laucevicius (Lithuania)
G. Lip (UK)
J.A. Lorenzo (Mexico)
N. Manak (Belarus)
G. Mancia (Italy)
M. Maranhao (Brazil)
J. Marco (Monaco)
F. Martinez (Argentina)
A. Maseri (Italy)
A. Matsumori (Japan)
A. Moustaghfir (Morocco)
O. Msalam (Libyan Arab Jamahiriya)
J. Murin (Slovak Republic)
H. Müderrisoğlu (Turkey)
F. Naccarella (Italy)
D. Nibouche (Algeria)
Y. Nişancı (Turkey)
R. Oganov (Russia)
A. Oğuz (Turkey)
A. Oktay (Turkey)
Ş. Oktay (Turkey)
L. Opie (South Africa)
H. Orer (Turkey)
A. Oto (Turkey)
I.E. Ovsyshcher (Israel)
A. Öncül (Turkey)
Z. Öngen (Turkey)
B. Özin (Turkey)
R. Paoletti (Italy)
J.G. Papp (Hungary)
A. Parkhomenko (Ukraine)
B. Petrovski (Macedonia)
B.N.C. Prichard (UK)
J. Polonia (Portugal)
M. Popovici (Moldova)
E. Raljevic (Bosnia and Herzegovina)
J.A. Ramirez (Brazil)
A. Ramzy (Egypt)
W. Remme (The Netherlands)
A.J. Reyes (Uruguay)
C. Risöe (Norway)
L. Alonso-Pulpon Rivera (Spain)
A. Rosei (Italy)
D. Roy (Canada)
E. Sade (Turkey)
V. Sansoy (Turkey)
S. Sasayama (Japan)
E. Schiffrin (Canada)
H.P. Schultheiss (Germany)
P. Seferovich (Serbia)
K. Sethi (India)
S. Sharma (India)
S. Sheikh (Pakistan)
B.N. Singh (USA)
M. Şahin (Turkey)
S. Stern (Israel)
J. Tamargo (Spain)
L. Tavazzi (Italy)
A. Tenenbaum (Israel)
T. Tezel (Turkey)
L. Tokgözoğlu (Turkey)
N. Toprak (Turkey)
A. Torbicki (Poland)
P. Tornvall (Sweden)
M. Tuncer (Turkey)
C. Türkoğlu (Turkey)
D. Tzivoni (Israel)
D. Ural (Turkey)
Y. Üresin (Turkey)
P.M. Vanhoutte (China)
P. Vardas (Greece)
S. Varini (Argentina)
L. Wallentin (Denmark)
O. Yeşildağ (Turkey)
A. Yıldırım (Turkey)
M. Yokoyama (Japan)
K. Zamolyi (Hungary)
D. Zipes (USA)

INTERNATIONAL SOCIETY OF CARDIOVASCULAR PHARMACOTHERAPY



EXECUTIVE BOARD

President

A. Bayés de Luna (Spain)

Immediate Past President / Treasurer

W. J. Louis (Australia)

Secretary

J. McNeil (Australia)

BOARD MEMBERS

J. Abrams (USA)	B. N. C. Prichard (UK)
A. Battler (Israel)	W. J. Remme (The Netherlands)
J. N. Cohn (USA)	S. Sasayama (Japan)
D. T. Kelly (Australia)	E. Schiffrin (Canada)
M. Maranhao (Brazil)	R. B. Singh (USA)
L. Opie (South Africa)	J. Tamargo (Spain)
R. Paoletti (Italy)	P. M. Vanhoutte (France)
P. A. Poole-Wilson (UK)	

FOUNDING MEMBERS

C. Kawai (Japan)
H. N. Neufeld (Israel)
E. Rappaport (USA)
W. Rutishauser (Switzerland)
S. Taylor (UK)

BUSINESS MANAGER

Marianne Burle de Figueiredo,
Taverna 39, 6575 San Nazzaro, Switzerland
Telephone : 0041 91 780 02 57
e-mail : marianne.bdf@vtx.ch

OFFICE OF THE PRESIDENT

Prof Antonio Bayés de Luna,
Institut Català Ciències Cardiovasculars,
St. Antoni M. Claret 167, 08025 Barcelona, Spain
Telephone : 0034 93 556 56 11
e-mail : abayes@csic-icc.org

www.iscpcardio.org

ISCP GOVERNORS

A. Capucci (Italia)	D. Hu (China)	A. Oto (Turkey)
A. Cieslinski (Poland)	J. C. Kaski (UK)	R. Pichardo (Dominican Republic)
P. Clemmensen (Denmark)	M. Kenda (Slovenia)	J. Polonia (Portugal)
D. V. Cokkinos (Greece)	B. M. Lombana (Panama)	J. A. Ramires (Brazil)
A. Damasceno (Mozambique)	J. A. Lorenzo (Mexico)	S. Satyavan (India)
G. A. Dan (Romania)	F. Martinez (Argentina)	H. P. Schultheiss (Germany)
N. Danchin (France)	A. Matsumori (Japan)	J. Sztajzel (Switzerland)
E. Escobar (Chile)	J. McNeil (Australia)	A. Tenenbaum (Israel)
J. R. Gonzalez-Juanatey (Spain)	P. Nilsson (Sweden)	W. H. van Gilst (The Netherlands)
N. Gotcheva (Bulgaria)	R. Oganov (Russia)	P. M. Vanhoutte (Hong Kong)
F. Hidalgo (Ecuador)	B. Olsson (Sweden)	

08:30-10:00 Plenary Session

Hall 1

Clinical trials in perspective**Chairs: Ç. Erol (Turkey), A. Bayés de Luna (Spain)**Progress and problems in randomized trials: From streptomycin to the era of mega trials *J. McNeil (Australia)*Efficacy and safety of clinical trials *J. Cohn (USA)*Placebo and nocebo in cardiovascular health: Implications for clinical trials ethics and patient-doctor relationship *P. A. Poole-Wilson (UK)*Minorities in clinical trials: Women and the elderly *M. Flather (UK)***10:00-10:30 Break****10:30-12:00 Debate**

Hall 1

Chairs: I. H. Ayhan (Turkey), W. H. van Gilst (The Netherlands)

I. In persons optimally treated with diuretics, ACE-inhibitors and beta blockers, aldosterone inhibitors are the next treatment not ARB's.

Pro. *P. A. Poole-Wilson (UK)*Con. *J. Cleland (UK)*

II. Antiplatelet therapy should be added to anticoagulant therapy in patients with AF and vascular disease?

Pro. *G. Lip (UK)*Con. *F. Verheugt (The Netherlands)*

III. A standart high dose statin is to be used in all patients at risk

Pro. *A. Fernandez-Cruz (Spain)*Con. *D. Duprez (USA)*

08:30-09:00 Opening Plenary Session**Hall 1****Neufeld Lecture****Chairs: A. Oto (Turkey), A. Bayés de Luna (Spain)**

First line treatment for hypertension. Is it time to change the paradigm from monotherapy to fixed dose ACE/Diuretic combination therapy?

*W. J. Louis (Australia)***09:00-10:00 Session****Hall 1****Antithrombotic therapy: An update****Chairs: Z. Öngen (Turkey), H. Ito (Japan)**

Antiplatelet therapy - Where are we now?

L. Wallentin (Sweden)

Oral anticoagulation - What is new?

F. Verheugt (The Netherlands)

Aspirin and clopidogrel resistance: Fact or fancy?

*G. Lip (UK)***10:00 -10:30 Break****10:30-12:00 Plenary Session****Hall 1****Clinical trials update****Chairs: M. Böhm (Germany), J. Cohn (USA)**

Clinical trials in AF

A. J. Camm (UK)

Clinical trials in HF

J. Cleland (UK)

Clinical trials in lipid disorders and atherosclerosis

M. R. Taskinen (Finland)

State of the art antithrombotic therapy 2007 (LMWH, fondaparinux, bivalirudin etc)

*F. Verheugt (The Netherlands)***12:00-13:30 Lunch****13:30-15:00 Core Curriculum****Hall 1****Pharmacotherapy of atrial fibrillation****Chairs: G. A. Dan (Romania), G. Breithardt (Germany)**

Historical perspectives

B. Lüderitz (Germany)

Rate control - Where are we now?

A. Capucci (Italy)

Rhythm control - What is new, what is to come?

A. J. Camm (UK)

Antithrombotic therapy and stroke risk stratification

*G. Lip (UK)***15:00-15:30 Break**

15:30-17:00 Joint Session of EAS and ISCP**Hall 1****Treating dislipidemia in 2007****Chair: M. R. Taskinen (Finland), W. J. Louis (Australia)**

Will raising HDL prevent atherosclerosis? New phramachologic options

L. Tokgözoğlu (Turkey)

Treating hypertriglyceridemia after FIELD

M. R. Taskinen (Finland)

What is new in LDL lowering?

V. Sansoy (Turkey)

Is inflammation a clinically relevant target for treatment of atherosclerosis?

*G. Hansson (Sweden)***17:00-17:30 Break****17:30-19:00 Plenary Session****Hall 1****Pharmacotherapy of hypertension: Beyond mega trials****Chairs: K. Stoschitzky (Austria), J. McNeil (Australia)**

Clinical trials and guidelines in hypertension - old drugs and new ones to come

C. Borghi (Italy)

Should pharmacogenetics influence our decision to treat?

W. J. Louis (Australia)

Future of beta blockers: Should we give them up in antihypertensive therapy?

B. N. C. Prichard (UK)

Beyond BP control

J. Cohn (USA)

08:30-10:00 Plenary Session

Hall 1

ACS: Paradigms and new perspectives in pharmacotherapy**Chairs: S. Sheikh (Pakistan), Y. Nişancı (Turkey)**

The early use of intravenous blockade in ACS.
What have we learned from COMMIT and COURAGE?

W. J. Louis (Australia)

Improving time to reperfusion therapy - the pivotal role of transfer of
ECG's from the field

P. Clemmensen (Denmark)

Triple antiplatelet therapy: When do we need it?

A. Battler (Israel)

Discharge therapy

N. Danchin (France)

Variability in response to antiplatelet therapy

L. Wallentin (Sweden)

08:30-10:00 Core Curriculum

Hall 2

New insights in the treatment of heart failure**Chairs: M. Böhm (Germany), D. V. Cokkinos (Greece)**

New biomarkers for the treatment of heart failure and cardiomyopathies

A. Matsumori (Japan)

Stem cell hope / hype in 2007

H. P. Schultheiss (Germany)

Emerging therapies for the management of decompensated heart failure

J. Tamargo (Spain)

Racial or ethnic response differences in heart failure

J. Cohn (USA)

Treatment of right heart failure

K. Aytemir (Turkey)

10:00-10:30 Break

10:30-12:00 Core Curriculum

Hall 1

Hypertension and heart failure continuum**Chairs: C. Borghi (Italy), S. Erdine (Turkey)**

From hypertension to heart failure: Pathophysiologic perspectives

W. J. Louis (Australia)

From blood pressure control to prevention and outcome improvement of heart failure

J. McNeil (Australia)

Hypertension and heart failure: Compelling indications for drug therapy

S. Sheikh (Pakistan)

10:30-12:00 Consensus Workshop**Hall 2****Pharmacotherapy in difficult entities****Chairs: F. Naccarella (Italy), K. Sethi (India)**Pharmacotherapy for inherited channelopathies *W. Zareba (USA)*New strategies in the therapy of inflammatory cardiomyopathy *H. P. Schultheiss (Germany)*Pharmacotherapy for sudden cardiac death *A. Raviolo (Italy)*Pharmacotherapy for pulmonary hypertension *L. Tokgözoğlu (Turkey)***12:00-13:30 Lunch****13:30-15:00 Joint Session of ISHNE and ISCP****Hall 1****Cardiovascular drug safety****Chairs: A. Capucci (Italy), A. J. Camm (UK)**Drug induced torsade des pointes: Mechanisms and scope of the problem *G. Breithardt (Germany)*Novel methods for QT and T wave monitoring in drug testing *W. Zareba (USA)*QRS safety (Na channel blockers) *N. El Sheriff (USA)*Drugs shorten sinus node *A. J. Camm (UK)*Cardiovascular effects of cox inhibitors and HDL levating drugs: Vioxx and torcetrapib story *G. Zareba (USA)***13:30-15:00 Symposium****Hall 2****New paradigms in RAAS inhibition strategies****Chairs: C. Uyan (Turkey), C. Tuncer (Turkey)**An ARB, an ACE-i or an ARB+ACE-i? *M. Böhm (Germany)*RAAS blockade. Towards the optimization by renin inhibitors *W. J. Louis (Australia)*Pleiotropic effects of ARB's: What have we learned from clinical trials? *F. Martinez (Argentina)*RAAS as a therapeutic target in diabetes *K. Stoschitzky (Austria)***15:00-15:30 Break**

15:30-17:00 Debate

Hall 1

Chairs: M. Zoghi (Turkey), K. Stoschitzky (Austria)

I. ACE inhibition is more effective than All receptor blockade in cardiovascular diseases

Pro.

W. H. van Gilst (The Netherlands)

Con.

M. Böhm (Germany)

II. The management of stable angina pectoris is medical not PCI

Pro.

P. A. Poole-Wilson (UK)

Con.

P. Serruys (The Netherlands)

15:30-17:00 Symposium

Hall 2

Hot issues in cardiovascular pharmacotherapy: Diabetes and cardiovascular system**Chairs: A. Oğuz (Turkey), A. Parkhomenko (Ukraine)**

Do new antidiabetics improve long - term survival?

Y. Üresin (Turkey)

Treatment of diabetic dislipidemia

D. Duprez (USA)

How to approach diabetic hypertensives

M. Abdulla (Sweden)

Insulin therapy in CCU

S. Akalın (Turkey)

17:00-17:30 Break

17:30-19:00 Core Curriculum

Hall 1

New targets in cardiovascular pharmacotherapy**Chairs: Ş. Oktay (Turkey), P. Clemmensen (Denmark)**

Slowing the heart rate

A. J. Camm (UK)

Endocannabinoid receptors

H. Müderrisoğlu (Turkey)

HDL raising

D. Duprez (USA)

PPAR Gamma

H. Orer (Turkey)

Oxidative stress and metabolic syndrome

M. Maranhao (Brazil)

17:30-19:00 Core Curriculum**Hall 2****Obesity*****Chairs: A. Matsumori (Japan), N. Gothceva (Bulgaria)***

Treating the obesity to reduce cardiovascular risk

A. Fernandez-Cruz (Spain)

Drug therapy for weight loss

J. R. Gonzalez- Juanatey (Spain)

Adipopectin and risk of ACS: Defining the obesity phenotype

V. Yumuk (Turkey)

Leptin and vascular function: A friend or foe?

D. Hu (China)

08:30-10:00 Consensus Workshop

Hall 1

Upstream therapy for atrial fibrillation**Chairs: B. Özin (Turkey), G. Lip (UK)**Outcome parameters in AF trials (Consensus Conferences of AFNET / EHRA) *G. Breithardt (Germany)*Statins *C. Jazzra (Lebanon)*Fishoil *F. Naccarella (Italy)*Antinflammatory drugs *G. A. Dan (Romania)***10:00-10:30 Break****10:30-12:00 Consensus Workshop**

Hall 1

Management of cardiovascular diseases in the elderly**Chairs: M. Kenda (Slovenia), A. Bayés de Luna (Spain)**Lipid management in the elderly: Is it even too late? *M. Kayıkçıoğlu (Turkey)*Management of hypertension in the elderly: Does age matter? *F. Follath (Switzerland)*The clinical cost/benefit of treatment of heart failure in the elderly.
Is excessive polypharmacy a major problem? *W. J. Louis (Australia)*Treatment of AF: How aggressive should be? *A. Capucci (Italy)*

GENERAL INFORMATION

Antalya

ATTALEIA of the ancient times, ANTALYA of the modern world with its small seaside towns offers an unbelievable richness to the travelers of any purpose with the natural and historical richness and the developments of the last decade.

The city is maybe the only one in the world where you can ski in the mornings on the valleys of white mountains (Taurus & Olympus) then enjoy a relaxing swim in the crystal-blue waters of Mediterranean in the afternoon. The waterfalls of Manavgat & Düden; the national parks of Olympus, Düzlerçamı, Yörük (Nomad where you can watch the traditional craftsman at work); the bays of Kemer, Tekirova, Çamyuva which are coined by the E.U. as the "Blue Flag-Clean Beach" are a few examples of Antalya's perfect natural beauty.

One of the oldest sites of settlement in the world (ruins found in the Karain Cave dates back to 50.000 BC the Paleolithic age) contains the remnants of the ancient Greeks, Romans, Seljuk's, and Ottomans; the city of Olympus, the gate of Hadrian, the temple of Diana, Chimera, the ancient cities of Perge, Aspendos, Thermessos, and Phaselis are a few examples we can cite here. ANTALYA one of the cities chosen to be developed as a tourist site by the World Bank has a lot of tourist facilities. The Aqua Park is able to offer nearly every kind of water-sports, the National Golf Park with its 18-hole golf course and 9 hole academy course is another attraction point. New establishments that are being opened in the area also offer new opportunities for sport fans.

The hotels of every category and the holiday resorts of all types offer qualified service to the visitors. It is possible to fulfill every holiday dream in Antalya.

ANTALYA "The Turkish Riviera" is also becoming one of the most favorable places of convention where the participants of meetings can fill their spare time with different activities. Most of the hotels in the area have meeting rooms of different sizes.

Congress Venue-Date

ISCP will be held between the dates of November 29th - December 02nd, 2007 in Sungate Port Royal Resort Hotel in Antalya, Turkey.

Language

The official language of the Congress is English. All communications will be in English but there will be Turkish-English simultaneous translation available for local participation.

Badges

Badges are essential for admission to the scientific sessions, social events and exhibition.

Certificate of Attendance

All the participants who attended the congress will receive their certificate of attendance on the last day of the Congress.

Exhibition and Sponsorship

An exhibition of pharmaceutical, technical and research products, equipments and services will be open during the congress. Possibilities for exhibition and several sponsorships are available please contact us at iscp2007@figur.net

Insurance and Liability

The Congress is not insured to meet any claims arising from any incidents during the Congress. It is the responsibility of participants, exhibitors and guests to be properly and adequately insured. The Congress organizers accept no responsibility for any loss of money or goods incurred by the participants.

Time Zone

GMT Time Zone (+2 Turkey, Antalya)

Visa Information

Passport and visa requirements may differ according to the country of origin. Please contact your travel agent or the Turkish Consulate or Embassy in your country for further advice. For more information please contact www.mfa.gov.tr

REGISTRATION

	Before September 01 st , 2007	After September 01 st , 2007
Physician	180.- EURO	240.- EURO
Physician in training	60.- EURO	150.- EURO
Nurse / Technician	60.- EURO	150.- EURO
Accompanying person	150.- EURO	180.- EURO
Exhibitor	150.- EURO	180.- EURO

18 % VAT is included.

* No cancellations can be made after September 01st, 2007, but name changes will be accepted.

Bank name : Yapi Kredi Bank
Branch name : Cankaya Cinnah Branch (code 942) / Ankara
Account name : ISCP2007
Account number : 802 462 69 (Euro)
Swiftcode : YAPITRISA
IBAN : TR910006701000000080246269

ACCOMMODATION

There are rooms reserved for our congress guests in the Congress Hotel. The cost of the hotel rooms is as follows:

	Before September 01 st , 2007		After September 01 st , 2007	
Hotel	Single Room Per Night	Double Room Per Night	Single Room Per Night	Double Room Per Night
Sungate Port Royal Resort	130.-EURO	165.-EURO	147,5.-EURO	212,5.-EURO

18 % VAT is included.

The hotel requires minimum 4 nights stay (arrival November 28th - departure December 02nd, 2007)

* No cancellations can be made after September 01st, 2007 but name changes will be accepted.

Accommodation is on New Wave Concept basis including:

- Open buffet breakfast
- Open buffet lunch
- Open buffet dinner
- Snack bars
- Unlimited drinks with meals
- Soft drinks and water in the minibar
- Unlimited drinks in hotel bars

Bank name : Garanti Bank
Branch name : Valikonagi Branch (code: 183) / Istanbul
Account name : ISCP2007
Account number : 909 23 37 (Euro)
Swiftcode : TGBATRIS 183
IBAN : TR30 0006 2000 1830 0009 0923 37



FIGÜR CONGRESS SERVICES

Ayazmaderesi Cad. Karadut Sok. No:7 34394 Dikilitaş - Istanbul / Turkey
 Phone: +90 212 258 60 20 pbx Fax: +90 212 258 60 78
 e-mail: iscp2007@figur.net

CONTACT ADDRESSES

Ali Oto, MD, FESC, FACC, FHRS

Cinnah Cad. No: 98/4

Çankaya 06550, Ankara - TURKEY

Tel: +90 312 440 20 21 Fax: +90 312 441 42 63

E-mail: alioto@superonline.com



FIGÜR CONGRESS SERVICES

Ayazmaderesi Cad. Karadut Sok. No:7

34394 Dikilitaş - İstanbul / Turkey

Phone: +90 212 258 60 20 pbx Fax: +90 212 258 60 78

e-mail: iscp2007@figur.net

www.iscp2007.org